All In Biotech

Drug Trial Radar · NCT07116889

A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD

A Phase 1 First in Human, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of GB-0895 in Adults With Mild to Moderate Asthma or Single Dose in Chronic Obstructive Pulmonary Disease (COPD)

Last checked: Nov 19, 2026Latest source record: Nov 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 156 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

156

Planned (sponsor's estimate)

Start

Dec 12, 2023

Primary completion

May 2027

Study completion May 2027

Sponsor

Lead sponsor
Generate BiomedicinesIndustry
Sponsor type
Industry
First posted
Aug 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is testing the safety, tolerability, pharmacokinetics and pharmacodynamics of GB-0895.

Conditions

  • Asthma
  • COPD (Chronic Obstructive Pulmonary Disease)

Interventions

  • GB-0895 (SC)Biological

    Single subcutaneous dose of GB-0895

  • GB-0895 (SC)Biological

    Multiple subcutaneous doses of GB-0895

  • Placebo (SC)Drug

    Single subcutaneous dose of placebo

  • Placebo (SC)Drug

    Multiple subcutaneous doses of placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment related adverse events as assessed by CTCAE 5.0Time frame: Day 1 to Day 500

Locations

13 sites in 3 countries. Site status is shown where the registry gives one.

  • Alcanza

    DeLand, Florida

  • Miami Research Institute of South Florida

    Miami, Florida

  • Omega Research

    Orlando, Florida

  • Nucleus Network

    Saint Paul, Minnesota

  • Southeastern Research Center

    Winston-Salem, North Carolina

  • DM Clinical Research

    Tomball, Texas

  • Charite Research Organization GmbH

    Berlin, Germany

  • IKF Pneumologie

    Frankfurt, Germany

  • Fraunhofer Institut fur Toxikologie and Experimentelle Medizin (ITEM)

    Hanover, Germany

  • Hammersmith Medicines Research

    London, United Kingdom

  • Queen Anne Street Medical Center

    London, United Kingdom

  • Medicines Evaluation Unit (MEU)

    Manchester, United Kingdom

  • Simbec-Orion Clinical Development

    Merthyr Tydfil, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.